Company Overview and News
ASX futures are down by 15 points, as Wall Street spent most of its day in the red — but managed to overcome its losses in the 11th hour.
HONG KONG (AP) — Asian stock indexes were mostly lower Friday as investors factored in fresh geopolitical uncertainty following the abrupt cancellation of a meeting between the U.S. and North Korean leaders.
The US investigation is said to be focused on illegal practices that can influence prices – such as spoofing, or flooding the market with fake orders to trick other traders into buying or selling
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
Shares of Nasdaq Inc. (NDAQ - Free Report) hit a new 52-week high of $91.94 on May 22, banking on solid April volumes as well as strong first-quarter results. With about 0.9 million shares traded in the last session, the stock closed at $91.51, gaining 0.3%. Solid Q1 Results Nasdaq's bottom line of $1.24 outpaced the Zacks Consensus Estimate by 5.1% and improved 31% year over year on higher revenues, sturdy volumes, a lower tax incidence and solid market share.
NEW YORK (AP) — U.S. stocks are falling Wednesday morning after a weak finish the day before, and energy and industrial companies are taking some of the worst losses. Investors are concerned about the European economy after a measure of business activity fell to an 18-month low in May. Target is sliding after big investments in its operations cut into its first-quarter profit while jewelry company Tiffany is climbing after a strong report.
The Dow Jones industrial average lost 108 points, or 0.4 percent, to 24,727. The Nasdaq composite fell 30 points, or 0.4 percent, to 7,348.
U.S. stock index futures pointed to a lower open on Wednesday after retail giant Target reported earnings that missed expectations while trade talks with China remained uncertain after President Donald Trump said Tuesday he was "not satisfied"with the discussions.
Stacey Cunningham, who is set to become the first woman president of the New York Stock Exchange, has said that she would pursue new types of financial listings and work to reverse the decline of international public offerings.
TOKYO (AP) — Asian indexes mostly slipped Wednesday amid continuing worries about North Korea after the perk from the easing of U.S.-China trade tensions faded.
Intel, the biggest maker of computer processors, said it found another vulnerability related to the chip security flaws announced this year.
WASHINGTON (AP) — The United States and China are working toward an agreement that would ease U.S. sanctions that were imposed on ZTE Corp. and let the Chinese telecommunications giant stay in business. President Donald Trump said Tuesday that the deal might require ZTE to revamp its board and to pay a fine of $1 billion or more. The ZTE talks occur after the U.S. and China over the weekend suspended plans to impose tariffs on as much as $200 billion in each other's goods, pulling back from the brink of a trade war.
NEW YORK (AP) — Technology companies and banks are rising Tuesday morning as U.S. stocks head higher for the second day in a row. Automakers are climbing after China said it will reduce auto import duties, another sign the two powers are resolving some of their differences on trade. Chipmaker Micron Technology is surging after it said it will buy back $10 billion in stock.
Stocks are opening broadly higher on Wall Street as the U.S. and China make more progress on defusing their trade tensions.
The New York Stock Exchange is set to get its first female leader in its 226-year history.
22h - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
22h - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
as of ET